Filtered By:
Management: National Institute for Health and Clinical Excelle
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 59 results found since Jan 2013.
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer du col de l'utérus avancé
Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8.ABSTRACTFrench recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of advanced cervical cancer The prognosis of cervical cancer remained pejorative until recently, first-line treatment consisting of platinum-based chemotherapy, associated with bevacizumab whenever possible, without any other therapeutic innovation for several years. However in 2022, immunotherapy appeared in the therapeutic landscape. Pembrolizumab can now be prescribed, thanks to the early access status granted by the HAS in September 2022, in pat...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Patricia Pautier Catherine Genestie Laurence Gladieff Jean-Emmanuel Kurtz Alain Lortholary Thibault de La Motte Rouge Anne-Lise Gaillard Anne Ducassou Coraline Dubot Etienne Rouleau Fabrice Narducci Sylvain Demontoy Christophe Hennequin Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
Bull Cancer. 2023 Jun;110(6S):6S34-6S43. doi: 10.1016/S0007-4551(23)00332-6.ABSTRACTRecommendations for clinical practice Nice/Saint-Paul-de-Vence 2022-2023 : Management of advanced/relapsing endometrial cancer Since the first recommendations in 2020 concerning metastatic and/or relapsed endometrial cancer, new treatment options have shown a benefit on patients' life expectancy, justifying their update. In first line, the choice will be made between chemotherapy with carboplatin/paclitaxel or hormone therapy with progestin, depending on tumor characteristics (histological type, grade, expression of hormone receptors, rate ...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: J érôme Alexandre Marie-Aude Le Fr ère-Belda Antoine Angelergues Gwena ël Ferron Isabelle Treilleux Anne-Lise Gaillard Jean-S ébastien Frenel Beno ît You Etienne Rouleau Alain Lortholary Isabelle Ray-Coquard Florence Joly Pour le groupe GINECO Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : prise en charge du cancer de l'endomètre localisé
Bull Cancer. 2023 Jun;110(6S):6S20-6S33. doi: 10.1016/S0007-4551(23)00331-4.ABSTRACTRecommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph n...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Alejandra Mart ínez Cyrus Chargari Elsa Kalbacher Anne-Lise Gaillard Alexandra Leary Martin Koskas Nicol ás Chopin Anne-Agathe Serre Anne-Claire Hardy-Bessard Ch érif Akladios Fabrice Lecuru Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer du col de l'utérus avancé
Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8.ABSTRACTFrench recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of advanced cervical cancer The prognosis of cervical cancer remained pejorative until recently, first-line treatment consisting of platinum-based chemotherapy, associated with bevacizumab whenever possible, without any other therapeutic innovation for several years. However in 2022, immunotherapy appeared in the therapeutic landscape. Pembrolizumab can now be prescribed, thanks to the early access status granted by the HAS in September 2022, in pat...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Patricia Pautier Catherine Genestie Laurence Gladieff Jean-Emmanuel Kurtz Alain Lortholary Thibault de La Motte Rouge Anne-Lise Gaillard Anne Ducassou Coraline Dubot Etienne Rouleau Fabrice Narducci Sylvain Demontoy Christophe Hennequin Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
Bull Cancer. 2023 Jun;110(6S):6S34-6S43. doi: 10.1016/S0007-4551(23)00332-6.ABSTRACTRecommendations for clinical practice Nice/Saint-Paul-de-Vence 2022-2023 : Management of advanced/relapsing endometrial cancer Since the first recommendations in 2020 concerning metastatic and/or relapsed endometrial cancer, new treatment options have shown a benefit on patients' life expectancy, justifying their update. In first line, the choice will be made between chemotherapy with carboplatin/paclitaxel or hormone therapy with progestin, depending on tumor characteristics (histological type, grade, expression of hormone receptors, rate ...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: J érôme Alexandre Marie-Aude Le Fr ère-Belda Antoine Angelergues Gwena ël Ferron Isabelle Treilleux Anne-Lise Gaillard Jean-S ébastien Frenel Beno ît You Etienne Rouleau Alain Lortholary Isabelle Ray-Coquard Florence Joly Pour le groupe GINECO Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : prise en charge du cancer de l'endomètre localisé
Bull Cancer. 2023 Jun;110(6S):6S20-6S33. doi: 10.1016/S0007-4551(23)00331-4.ABSTRACTRecommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph n...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Alejandra Mart ínez Cyrus Chargari Elsa Kalbacher Anne-Lise Gaillard Alexandra Leary Martin Koskas Nicol ás Chopin Anne-Agathe Serre Anne-Claire Hardy-Bessard Ch érif Akladios Fabrice Lecuru Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer du col de l'utérus avancé
Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8.ABSTRACTFrench recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of advanced cervical cancer The prognosis of cervical cancer remained pejorative until recently, first-line treatment consisting of platinum-based chemotherapy, associated with bevacizumab whenever possible, without any other therapeutic innovation for several years. However in 2022, immunotherapy appeared in the therapeutic landscape. Pembrolizumab can now be prescribed, thanks to the early access status granted by the HAS in September 2022, in pat...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Patricia Pautier Catherine Genestie Laurence Gladieff Jean-Emmanuel Kurtz Alain Lortholary Thibault de La Motte Rouge Anne-Lise Gaillard Anne Ducassou Coraline Dubot Etienne Rouleau Fabrice Narducci Sylvain Demontoy Christophe Hennequin Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
Bull Cancer. 2023 Jun;110(6S):6S34-6S43. doi: 10.1016/S0007-4551(23)00332-6.ABSTRACTRecommendations for clinical practice Nice/Saint-Paul-de-Vence 2022-2023 : Management of advanced/relapsing endometrial cancer Since the first recommendations in 2020 concerning metastatic and/or relapsed endometrial cancer, new treatment options have shown a benefit on patients' life expectancy, justifying their update. In first line, the choice will be made between chemotherapy with carboplatin/paclitaxel or hormone therapy with progestin, depending on tumor characteristics (histological type, grade, expression of hormone receptors, rate ...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: J érôme Alexandre Marie-Aude Le Fr ère-Belda Antoine Angelergues Gwena ël Ferron Isabelle Treilleux Anne-Lise Gaillard Jean-S ébastien Frenel Beno ît You Etienne Rouleau Alain Lortholary Isabelle Ray-Coquard Florence Joly Pour le groupe GINECO Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : prise en charge du cancer de l'endomètre localisé
Bull Cancer. 2023 Jun;110(6S):6S20-6S33. doi: 10.1016/S0007-4551(23)00331-4.ABSTRACTRecommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph n...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Alejandra Mart ínez Cyrus Chargari Elsa Kalbacher Anne-Lise Gaillard Alexandra Leary Martin Koskas Nicol ás Chopin Anne-Agathe Serre Anne-Claire Hardy-Bessard Ch érif Akladios Fabrice Lecuru Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer du col de l'utérus avancé
Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8.ABSTRACTFrench recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of advanced cervical cancer The prognosis of cervical cancer remained pejorative until recently, first-line treatment consisting of platinum-based chemotherapy, associated with bevacizumab whenever possible, without any other therapeutic innovation for several years. However in 2022, immunotherapy appeared in the therapeutic landscape. Pembrolizumab can now be prescribed, thanks to the early access status granted by the HAS in September 2022, in pat...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Patricia Pautier Catherine Genestie Laurence Gladieff Jean-Emmanuel Kurtz Alain Lortholary Thibault de La Motte Rouge Anne-Lise Gaillard Anne Ducassou Coraline Dubot Etienne Rouleau Fabrice Narducci Sylvain Demontoy Christophe Hennequin Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
Bull Cancer. 2023 Jun;110(6S):6S34-6S43. doi: 10.1016/S0007-4551(23)00332-6.ABSTRACTRecommendations for clinical practice Nice/Saint-Paul-de-Vence 2022-2023 : Management of advanced/relapsing endometrial cancer Since the first recommendations in 2020 concerning metastatic and/or relapsed endometrial cancer, new treatment options have shown a benefit on patients' life expectancy, justifying their update. In first line, the choice will be made between chemotherapy with carboplatin/paclitaxel or hormone therapy with progestin, depending on tumor characteristics (histological type, grade, expression of hormone receptors, rate ...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: J érôme Alexandre Marie-Aude Le Fr ère-Belda Antoine Angelergues Gwena ël Ferron Isabelle Treilleux Anne-Lise Gaillard Jean-S ébastien Frenel Beno ît You Etienne Rouleau Alain Lortholary Isabelle Ray-Coquard Florence Joly Pour le groupe GINECO Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : prise en charge du cancer de l'endomètre localisé
Bull Cancer. 2023 Jun;110(6S):6S20-6S33. doi: 10.1016/S0007-4551(23)00331-4.ABSTRACTRecommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph n...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Alejandra Mart ínez Cyrus Chargari Elsa Kalbacher Anne-Lise Gaillard Alexandra Leary Martin Koskas Nicol ás Chopin Anne-Agathe Serre Anne-Claire Hardy-Bessard Ch érif Akladios Fabrice Lecuru Source Type: research
